Zentalis Pharmaceuticals IncNASDAQ:ZNTL
- LAST PRICE3.4700
- TODAY'S CHANGE (%)-0.4800 (-12.1519%)
- Bid / Lots3.4700/ 8
- Ask / Lots3.4800/ 14
- Open / Previous Close3.9900 / 3.9500
- Day Range
- 52 Week Range
- Volume1,018,283
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ZNTL |
|---|---|---|
| 09:32 ET | 18809 | 4 |
| 09:33 ET | 10852 | 3.97 |
| 09:35 ET | 20388 | 3.76 |
| 09:37 ET | 4556 | 3.71 |
| 09:39 ET | 8024 | 3.71 |
| 09:42 ET | 6126 | 3.655 |
| 09:44 ET | 48249 | 3.58 |
| 09:46 ET | 9312 | 3.55 |
| 09:48 ET | 23836 | 3.555 |
| 09:50 ET | 25628 | 3.55 |
| 09:51 ET | 11643 | 3.56 |
| 09:53 ET | 16453 | 3.565 |
| 09:55 ET | 3900 | 3.5473 |
| 09:57 ET | 7970 | 3.555 |
| 10:00 ET | 1901 | 3.535 |
| 10:02 ET | 6336 | 3.5 |
| 10:04 ET | 6325 | 3.51 |
| 10:06 ET | 11979 | 3.515 |
| 10:08 ET | 22671 | 3.585 |
| 10:09 ET | 29755 | 3.62 |
| 10:11 ET | 8262 | 3.605 |
| 10:13 ET | 11961 | 3.625 |
| 10:15 ET | 11828 | 3.615 |
| 10:18 ET | 38051 | 3.635 |
| 10:20 ET | 24486 | 3.645 |
| 10:22 ET | 10727 | 3.625 |
| 10:24 ET | 4000 | 3.615 |
| 10:26 ET | 12846 | 3.62 |
| 10:27 ET | 4021 | 3.625 |
| 10:29 ET | 15816 | 3.63 |
| 10:31 ET | 9056 | 3.615 |
| 10:33 ET | 10167 | 3.5825 |
| 10:36 ET | 4834 | 3.575 |
| 10:38 ET | 5892 | 3.585 |
| 10:40 ET | 3145 | 3.575 |
| 10:42 ET | 5119 | 3.575 |
| 10:44 ET | 6300 | 3.565 |
| 10:45 ET | 3900 | 3.565 |
| 10:47 ET | 5186 | 3.575 |
| 10:49 ET | 19457 | 3.575 |
| 10:51 ET | 7703 | 3.585 |
| 10:54 ET | 5556 | 3.565 |
| 10:56 ET | 5908 | 3.535 |
| 10:58 ET | 14265 | 3.53 |
| 11:00 ET | 7401 | 3.565 |
| 11:02 ET | 5060 | 3.525 |
| 11:03 ET | 5473 | 3.535 |
| 11:05 ET | 8428 | 3.525 |
| 11:07 ET | 6060 | 3.545 |
| 11:09 ET | 1330 | 3.555 |
| 11:12 ET | 12295 | 3.54 |
| 11:14 ET | 3893 | 3.535 |
| 11:16 ET | 8974 | 3.585 |
| 11:18 ET | 3818 | 3.585 |
| 11:20 ET | 5260 | 3.565 |
| 11:21 ET | 14020 | 3.54 |
| 11:23 ET | 7424 | 3.5625 |
| 11:25 ET | 3100 | 3.565 |
| 11:27 ET | 5260 | 3.545 |
| 11:30 ET | 2600 | 3.535 |
| 11:32 ET | 7208 | 3.525 |
| 11:34 ET | 4548 | 3.505 |
| 11:36 ET | 42600 | 3.471 |
| 11:38 ET | 6934 | 3.465 |
| 11:39 ET | 5274 | 3.465 |
| 11:41 ET | 5289 | 3.455 |
| 11:43 ET | 3849 | 3.45 |
| 11:45 ET | 8125 | 3.455 |
| 11:48 ET | 5385 | 3.455 |
| 11:50 ET | 3800 | 3.455 |
| 11:52 ET | 4063 | 3.455 |
| 11:54 ET | 4292 | 3.455 |
| 11:56 ET | 7169 | 3.46 |
| 11:57 ET | 9574 | 3.4401 |
| 11:59 ET | 10177 | 3.47 |
| 12:01 ET | 7935 | 3.435 |
| 12:03 ET | 7525 | 3.415 |
| 12:06 ET | 2080 | 3.425 |
| 12:08 ET | 2589 | 3.4125 |
| 12:10 ET | 4467 | 3.415 |
| 12:12 ET | 4599 | 3.405 |
| 12:14 ET | 3908 | 3.405 |
| 12:15 ET | 5573 | 3.405 |
| 12:17 ET | 15380 | 3.395 |
| 12:19 ET | 6288 | 3.405 |
| 12:21 ET | 4753 | 3.405 |
| 12:24 ET | 220 | 3.405 |
| 12:26 ET | 1487 | 3.405 |
| 12:28 ET | 614 | 3.405 |
| 12:30 ET | 8082 | 3.405 |
| 12:32 ET | 7099 | 3.44 |
| 12:33 ET | 2180 | 3.445 |
| 12:35 ET | 3169 | 3.45 |
| 12:37 ET | 3391 | 3.455 |
| 12:39 ET | 1397 | 3.455 |
| 12:42 ET | 13436 | 3.46 |
| 12:44 ET | 5007 | 3.455 |
| 12:46 ET | 751 | 3.455 |
| 12:48 ET | 3174 | 3.455 |
| 12:50 ET | 1341 | 3.455 |
| 12:51 ET | 7448 | 3.455 |
| 12:53 ET | 6589 | 3.465 |
| 12:55 ET | 2112 | 3.465 |
| 12:57 ET | 1500 | 3.465 |
| 01:00 ET | 14424 | 3.47 |
Today
Nov 13, 2024
DJ Zentalis Pharmaceuticals Adds New Executives as Efforts Around Azenosertib Sharpen, from 8:22AM ET on Wednesday Nov 13, 2024 by Dow Jones
8:22AM ET on Wednesday Nov 13, 2024 by Dow JonesZentalis Pharmaceuticals Announces Executive Leadership Changes Supporting Planned Registrational Clinical Studies of Azenosertib, from 8:01AM ET on Wednesday Nov 13, 2024 by Dow Jones
8:01AM ET on Wednesday Nov 13, 2024 by Dow JonesPress Release: Zentalis Pharmaceuticals Announces Executive Leadership Changes Supporting Planned Registrational Clinical Studies of Azenosertib, from 8:01AM ET on Wednesday Nov 13, 2024 by Dow Jones
8:01AM ET on Wednesday Nov 13, 2024 by Dow Jones
Nov 1, 2024
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 7:04PM ET on Friday Nov 01, 2024 by Dow Jones
7:04PM ET on Friday Nov 01, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Zentalis Pharmaceuticals Inc | 280.9M | -1.4x | --- |
Atea Pharmaceuticals Inc | 279.4M | -1.6x | --- |
Kodiak Sciences Inc | 278.9M | -1.5x | --- |
aTyr Pharma Inc | 267.8M | -3.1x | --- |
Biomea Fusion Inc | 257.7M | -1.7x | --- |
Lexeo Therapeutics Inc | 257.2M | -2.5x | --- |
Company Information
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company’s lead product candidate includes azenosertib (ZN-c3), which is a WEE1 inhibitor for advanced solid tumors and hematological malignancies. The Company is also developing a BCL-2 inhibitor, ZN-d5, for hematological malignancies and related disorders. ZN-d5 is being evaluated in combination with azenosertib in a Phase I/II dose escalation clinical trial in patients with R/R acute myeloid leukemia (AML) (ZN-d5-004C). The Company is also advancing its research on protein degraders and other undisclosed targets using its Integrated Discovery Engine.
Contact Information
- Headquarters
- 10275 Science Center Drive, Suite 200SAN DIEGO, CA, United States 92121
- Phone
- 858-263-4333
- Fax
- 302-655-5049
Executives
- Chairman of the Board
- Scott Myers
- President, Chief Executive Officer, Director
- Julie Eastland
- Senior Vice President, Finance, Interim Principal Accounting Officer and Principal Financial Officer
- Vincent Vultaggio
- Chief Scientific Officer
- Mark Lackner,
- Chief Medical Officer
- Ingmar Bruns
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $280.9M |
|---|---|
Revenue (TTM) | $40.6M |
Shares Outstanding | 71.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.84 |
EPS | $-2.53 |
Book Value | $6.18 |
P/E Ratio | -1.4x |
Price/Sales (TTM) | 6.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -515.94% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
